ClinVar Miner

Submissions for variant NM_000492.4(CFTR):c.2428A>T (p.Arg810Ter)

dbSNP: rs377447726
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV001001123 SCV001158263 pathogenic not specified 2019-03-14 criteria provided, single submitter clinical testing The CFTR c.2428A>T; p.Arg810Ter variant (rs377447726), to our knowledge, is not reported in the medical literature or gene-specific databases. This variant is also absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. This variant induces an early termination codon and is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. CFTR loss-of-function is an established mechanism of disease, and truncating variants downstream of p.Arg810Ter have been reported in individuals with cystic fibrosis and are considered pathogenic (Shackleton 1994, CFTR2 database). Based on available information, the p.Arg810Ter variant is considered to be pathogenic. References: CFTR2 database: https://cftr2.org/ Shackleton S et al. Identification of rare and novel mutations in the CFTR genes of CF patients in southern England. Hum Mutat. 1994;3(2):141-51.
Labcorp Genetics (formerly Invitae), Labcorp RCV001056339 SCV001220780 pathogenic Cystic fibrosis 2019-05-02 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922). This variant has not been reported in the literature in individuals with CFTR-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Arg810*) in the CFTR gene. It is expected to result in an absent or disrupted protein product.
Ambry Genetics RCV001056339 SCV005561213 pathogenic Cystic fibrosis 2024-11-15 criteria provided, single submitter clinical testing The p.R810* pathogenic mutation (also known as c.2428A>T), located in coding exon 14 of the CFTR gene, results from an A to T substitution at nucleotide position 2428. This changes the amino acid from an arginine to a stop codon within coding exon 14. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.